Related Experiment Video

Updated: Nov 3, 2025

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

411

Sodium-glucose cotransporter 2 inhibition in non-diabetic kidney disease

Mohanad Almaimani1,2, Vikas S Sridhar1,3,4, David Z I Cherney1,3,4,5

  • 1Department of Medicine, Division of Nephrology, University of Toronto, Canada.

Current Opinion in Nephrology and Hypertension
|June 2, 2021
PubMed
Abstract

Insights

Sodium-glucose cotransporter 2 (SGLT2) inhibitors offer kidney protection beyond diabetes. Recent trials show SGLT2 inhibition benefits patients with nondiabetic kidney disease, supporting its use in broader CKD populations.

Area of Science:

  • Nephrology
  • Pharmacology
  • Cardiology

Background:

  • Sodium-glucose cotransporter 2 (SGLT2) inhibitors demonstrate cardiorenal benefits in diabetic populations.
  • Established efficacy in cardiovascular outcome trials (CVOTs) and CREDENCE for diabetic kidney disease (DKD).

Purpose of the Study:

  • To review mechanisms of kidney protection by SGLT2 inhibitors.
  • To evaluate SGLT2 inhibition in nondiabetic kidney disease (non-DKD) populations.

Main Methods:

  • Review of translational studies and clinical trials.
  • Analysis of DAPA CKD trial data.
  • Examination of preclinical studies and post hoc analyses.

Main Results:

  • DAPA CKD trial extends cardiorenal protection to non-DKD patients.
  • CREDENCE trial showed a 30% risk reduction in kidney outcomes for DKD.
  • SGLT2 inhibitor benefits are independent of glucose-lowering effects.

Conclusions:

  • Growing evidence supports SGLT2 inhibitors for kidney protection in non-DKD patients.
  • Strong rationale for integrating SGLT2 inhibition into standard care for specific non-DKD groups.

More Related Videos

Assessment of Kidney Function in Mouse Models of Glomerular Disease09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

18.0K
Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes08:03

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

Published on: June 25, 2017

20.3K

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
26.4K
Secondary Active Transport01:55

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
132.8K
Secondary Active Transport01:32

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
8.6K
Glucose Absorption Into the Small Intestine01:26

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
33.5K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
315
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
380